A large observational study out of the University of Hong Kong has found that a common class of osteoporosis drugs is associated with a meaningfully lower risk of dementia — a result that has drawn fresh attention this week even though it was first published in the journal Alzheimer's & Dementia in July 2025.
Researchers led by Ching-Lung Cheung at HKUMed tracked more than 120,000 Hong Kong residents age 60 and older with osteoporosis or a fragility fracture, using citywide electronic medical records spanning 2005 to 2020. Patients who took nitrogen-containing bisphosphonates — a drug class that includes alendronate and zoledronate, widely prescribed to strengthen bone — had a 16 percent lower risk of developing dementia than patients who received no osteoporosis treatment at all, and a 24 percent lower risk than patients treated with other kinds of osteoporosis drugs. The researchers estimate that treating 48 patients with a bisphosphonate for five years would prevent one case of dementia; the association was strongest among women and among patients who had already suffered a hip fracture.
A finding with real limits
"Our study provides evidence that [bisphosphonates] may offer dual benefits in strengthening bones and reducing fracture risk," Cheung said, noting the drugs "can also provide additional protection for high-risk populations" as society ages. But Cheung was careful to flag the limits of the finding: "Our findings therefore do not prove that bisphosphonate use reduces dementia risk; this needs confirmation in a clinical trial."
That caveat matters because the study is observational, not a randomized trial — it can show an association but cannot rule out other explanations, such as healthier patients being more likely to receive and tolerate the drugs in the first place. The researchers also lacked data on osteoporosis severity, fracture severity, or patients' use of over-the-counter calcium and vitamin D, any of which could confound the result, and the entire cohort was drawn from a single Chinese population, limiting how confidently the finding can be generalized elsewhere.
The study's return to headlines this week — more than a year after its original publication — appears to be driven by a fresh HKUMed press release recirculated via ScienceDaily rather than any new data. Bisphosphonates remain a first-line treatment for osteoporosis regardless of the dementia question, and doctors are not expected to change prescribing based on an observational link alone. Cheung's team says the next step is a clinical trial that could establish, one way or the other, whether the drugs already sitting in millions of medicine cabinets are doing double duty.
